Phapros Tbk PT (PEHA) - Total Assets
Based on the latest financial reports, Phapros Tbk PT (PEHA) holds total assets worth Rp1.46 Trillion IDR (≈ $85.42 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net assets of Phapros Tbk PT for net asset value and shareholders' equity analysis.
Phapros Tbk PT - Total Assets Trend (2011–2024)
This chart illustrates how Phapros Tbk PT's total assets have evolved over time, based on quarterly financial data.
Phapros Tbk PT - Asset Composition Analysis
Current Asset Composition (December 2024)
Phapros Tbk PT's total assets of Rp1.46 Trillion consist of 44.1% current assets and 55.9% non-current assets.
| Asset Category | Amount (IDR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rp400.00 Million | 6.4% |
| Accounts Receivable | Rp336.61 Billion | 23.5% |
| Inventory | Rp168.59 Billion | 11.8% |
| Property, Plant & Equipment | Rp506.57 Billion | 35.4% |
| Intangible Assets | Rp5.07 Billion | 0.4% |
| Goodwill | Rp53.68 Billion | 3.8% |
Asset Composition Trend (2011–2024)
This chart illustrates how Phapros Tbk PT's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Phapros Tbk PT worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Phapros Tbk PT's current assets represent 44.1% of total assets in 2024, a decrease from 82.0% in 2011.
- Cash Position: Cash and equivalents constituted 6.4% of total assets in 2024, up from 4.4% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 0.0% in 2011.
- Asset Diversification: The largest asset category is property, plant & equipment at 35.4% of total assets.
Phapros Tbk PT Competitors by Total Assets
Key competitors of Phapros Tbk PT based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Daihan Pharmaceutical Co.Ltd
KQ:023910
|
Korea | ₩344.02 Billion |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA
|
India | Rs525.46 Billion |
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999
|
China | CN¥56.56 Billion |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538
|
China | CN¥4.75 Billion |
|
Zhejiang Xianju Pharmaceutical Co Ltd
SHE:002332
|
China | CN¥7.26 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥2.26 Billion |
|
Zhejiang Cheng Yi Pharmaceutical Co Ltd
SHG:603811
|
China | CN¥1.69 Billion |
|
Hainan Honz Pharmaceutical Co
SHE:300086
|
China | CN¥1.88 Billion |
Phapros Tbk PT - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.30 | 1.23 | 0.96 |
| Quick Ratio | 0.99 | 0.84 | 0.65 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Rp160.14 Billion | Rp166.73 Billion | Rp-60.77 Billion |
Phapros Tbk PT - Advanced Valuation Insights
This section examines the relationship between Phapros Tbk PT's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.71 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -19.0% |
| Total Assets | Rp1.43 Trillion |
| Market Capitalization | $14.67 Million USD |
Valuation Analysis
Below Book Valuation: The market values Phapros Tbk PT's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Phapros Tbk PT's assets decreased by 19.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Phapros Tbk PT (2011–2024)
The table below shows the annual total assets of Phapros Tbk PT from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Rp1.43 Trillion ≈ $83.79 Million |
-19.02% |
| 2023-12-31 | Rp1.77 Trillion ≈ $103.47 Million |
-2.24% |
| 2022-12-31 | Rp1.81 Trillion ≈ $105.84 Million |
-1.75% |
| 2021-12-31 | Rp1.84 Trillion ≈ $107.73 Million |
-4.04% |
| 2020-12-31 | Rp1.92 Trillion ≈ $112.27 Million |
-8.62% |
| 2019-12-31 | Rp2.10 Trillion ≈ $122.86 Million |
+12.20% |
| 2018-12-31 | Rp1.87 Trillion ≈ $109.50 Million |
+58.91% |
| 2017-12-31 | Rp1.18 Trillion ≈ $68.91 Million |
+33.13% |
| 2016-12-31 | Rp883.29 Billion ≈ $51.76 Million |
+29.77% |
| 2015-12-31 | Rp680.65 Billion ≈ $39.88 Million |
+6.67% |
| 2014-12-31 | Rp638.09 Billion ≈ $37.39 Million |
-0.78% |
| 2013-12-31 | Rp643.09 Billion ≈ $37.68 Million |
+15.12% |
| 2012-12-31 | Rp558.64 Billion ≈ $32.73 Million |
+20.76% |
| 2011-12-31 | Rp462.59 Billion ≈ $27.11 Million |
-- |
About Phapros Tbk PT
PT Phapros Tbk, together with its subsidiaries, operates in the pharmaceutical industry in Indonesia. The company operates through Ethical; Over the Counter (OTC) Drugs; Generic Drugs Bearing (OCB); and Toll-in segments. It offers OTC drugs, including Antimo Anak, Antimo tablet, Livron B Plex, X-Gra, Becefort Sirop and tablet, Noza, Febrinex, Betafort suspensi, and Hemorogard. The company also pr… Read more